Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06223880 · ClinicalTrials.gov registry record · Phase 4
A Study to Evaluate the Efficacy of AXS-05 Compared to Bupropion in Preventing the Relapse of Depressive Symptoms
A Phase 4 study of Major Depressive Disorder, sponsored by Axsome Therapeutics.
- Recruiting
- Registry status
- Phase 4
- Development phase
- 350
- Enrollment target
- 20
- Study locations
NCT06223880 is a Phase 4 study of Major Depressive Disorder that is actively recruiting participants, run by Axsome Therapeutics. The registered enrollment target is 350 participants, roughly in line with the 376-participant average among 282 other Major Depressive Disorder trials with a reported enrollment target. The trial reports 20 study locations across 7 states.
The verdict
NCT06223880, a Phase 4 study of Major Depressive Disorder, is actively recruiting participants, sponsored by Axsome Therapeutics.
- RECRUITING
- Registry status
- Phase 4
- Development phase
- 350 participants
- Enrollment target
- 20
- Study locations
Study Summary
This is a randomized, double-blind, active-controlled, multi-center study to evaluate the efficacy of AXS-05, compared to bupropion, in preventing the relapse of depressive symptoms in subjects with major depressive disorder (MDD) who have responded to treatment with AXS-05.
Conditions Studied
Interventions
- DRUG AXS-05
- DRUG Bupropion
Study Locations (20)
Florida
- Clinical Research Site - Brandon
- Clinical Research Site - Doral
- Clinical Research Site - Hialeah
- Clinical Research Site - Jacksonville
- Clinical Research Site - Miami
- Clinical Research Site - Orlando
- Clinical Research Site - Orlando
- Clinical Research Site - Orlando
California
- Clinical Research Site - Bellflower
- Clinical Research Site - Lafayette
- Clinical Research Site - Oceanside
- Clinical Research Site - Redlands
- Clinical Research Site - Riverside
- Clinical Research Site - San Diego
- Clinical Research Site - Upland
Georgia
- Clinical Research Site - Atlanta
Illinois
- Clinical Research Site - Chicago
Kansas
- Clinical Research Site - Overland Park
Louisiana
- Clinical Research Site - New Orleans
Massachusetts
- Clinical Research Site - Boston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 350 participants |
| Start Date | 2023-12-27 |
| Est. Completion | 2026-03 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06223880
The ClinicalTrials.gov registry entry for NCT06223880 describes a study currently listed as recruiting, categorized as Phase 4. The registered enrollment target is 350 participants, a figure that helps gauge the scale of data the investigators plan to collect, roughly in line with the 376-participant average among 282 other Major Depressive Disorder trials with a reported enrollment target. The listed sponsor is Axsome Therapeutics, which has 28 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Major Depressive Disorder appearing as the primary indexed condition, and to 2 interventions - of which AXS-05 is the first listed.
NCT06223880 reports 20 study locations spanning 7 distinct geographic areas - top geographies include Florida, California, Georgia.
Frequently Asked Questions
What is clinical trial NCT06223880 about?
NCT06223880 is a clinical study titled "A Study to Evaluate the Efficacy of AXS-05 Compared to Bupropion in Preventing the Relapse of Depressive Symptoms". This is a randomized, double-blind, active-controlled, multi-center study to evaluate the efficacy of AXS-05, compared to bupropion, in preventing the relapse of depressive symptoms in subjects with major depressive disorder (MDD) who have responded to treatment with AXS-05.
What is the current status of trial NCT06223880?
This trial is currently recruiting. It is a Phase 4 study. The enrollment target is 350 participants. The study started on 2023-12-27. Estimated completion is 2026-03.
What conditions does trial NCT06223880 study?
This clinical trial studies the following conditions: Major Depressive Disorder.
What interventions are being tested in trial NCT06223880?
The interventions under investigation include: AXS-05 (DRUG), Bupropion (DRUG).
Who is sponsoring clinical trial NCT06223880?
This trial is sponsored by Axsome Therapeutics, which has 28 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06223880 being conducted?
This trial has 20 study locations across California, Florida, Georgia, Illinois, Kansas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Major Depressive Disorder
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study to Evaluate the Effectiveness of Valbenazine in Adult Participants With Tardive Dyskinesia (TD) Who Remain Symptomatic While Receiving or After Stopping a Vesicular Monoamine Transporter 2 (VMAT2) Inhibitor
RECRUITING · Phase 4
-
Establishing Multimodal Brain Biomarkers for Treatment Selection in Depression
RECRUITING · Phase 4
-
Neural Circuit Effects of Ketamine in Depression
RECRUITING · Phase 4
-
Aβ Dynamics in LLMD
RECRUITING · Phase 4
-
Long-Term Maintenance With Ketamine and Esketamine for Reduction of Suicide in High-Risk Patients With Depression
RECRUITING · Phase 4
-
Ovarian Hormone Withdrawal, Anhedonia, and Reward Sensitivity in Women With Premenstrual Exacerbations of Depression
RECRUITING · Phase 4
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.